132 related articles for article (PubMed ID: 38219394)
1. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
[TBL] [Abstract][Full Text] [Related]
2. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
3. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
[TBL] [Abstract][Full Text] [Related]
4. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
Di Gregorio M; Torri Clerici VLA; Fenu G; Gaetani L; Gallo A; Cavalla P; Ragonese P; Annovazzi P; Gajofatto A; Prosperini L; Landi D; Nicoletti CG; Di Carmine C; Totaro R; Nociti V; De Fino C; Ferraro D; Tomassini V; Tortorella C; Righini I; Amato MP; Manni A; Paolicelli D; Iaffaldano P; Lanzillo R; Moccia M; Buttari F; Fantozzi R; Cerqua R; Zagaglia S; Farina D; De Luca G; Buscarinu MC; Pinardi F; Cocco E; Gasperini C; Solaro CM; Di Filippo M
Eur J Neurol; 2021 Apr; 28(4):1299-1307. PubMed ID: 33305459
[TBL] [Abstract][Full Text] [Related]
5. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
Jain RS; Khan I; Kandelwal K; Desai T
Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
[TBL] [Abstract][Full Text] [Related]
6. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
Sechi E; Krecke KN; Messina SA; Buciuc M; Pittock SJ; Chen JJ; Weinshenker BG; Lopez-Chiriboga AS; Lucchinetti CF; Zalewski NL; Tillema JM; Kunchok A; Monaco S; Morris PP; Fryer JP; Nguyen A; Greenwood T; Syc-Mazurek SB; Keegan BM; Flanagan EP
Neurology; 2021 Sep; 97(11):e1097-e1109. PubMed ID: 34261784
[TBL] [Abstract][Full Text] [Related]
7. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
8. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
9. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
[TBL] [Abstract][Full Text] [Related]
10. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
11. Baló's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures.
Jarius S; Würthwein C; Behrens JR; Wanner J; Haas J; Paul F; Wildemann B
J Neuroinflammation; 2018 Jan; 15(1):22. PubMed ID: 29347989
[TBL] [Abstract][Full Text] [Related]
12. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
Jeong IH; Kim SH; Hyun JW; Joung A; Cho HJ; Kim HJ
J Neurol Sci; 2015 Nov; 358(1-2):118-24. PubMed ID: 26333950
[TBL] [Abstract][Full Text] [Related]
13. Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.
Fereidan-Esfahani M; Decker PA; Eckel Passow JE; Lucchinetti CF; Flanagan EP; Tobin WO
Eur J Neurol; 2022 Mar; 29(3):782-789. PubMed ID: 34773343
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology.
Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF
Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252
[TBL] [Abstract][Full Text] [Related]
15. Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series.
Boyle T; Fernando SL; Drummond J; Fontes A; Parratt J
Front Neurol; 2023; 14():1092373. PubMed ID: 36816572
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations.
Li X; Miao X; Wang Y; Sun J; Gao H; Han J; Li Y; Wang Q; Sun C; Liu J
Front Immunol; 2022; 13():1052678. PubMed ID: 36532021
[TBL] [Abstract][Full Text] [Related]
17. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
[TBL] [Abstract][Full Text] [Related]
18. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
[TBL] [Abstract][Full Text] [Related]
19. Tumefactive demyelination: clinical, imaging and follow-up observations in thirty-nine patients.
Nagappa M; Taly AB; Sinha S; Bharath RD; Mahadevan A; Bindu PS; Saini JS; Prasad C; Shankar SK
Acta Neurol Scand; 2013 Jul; 128(1):39-47. PubMed ID: 23277913
[TBL] [Abstract][Full Text] [Related]
20. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
